CANCELED: VIP Receptors-Targeted Nanomedicines

H. Onyuksel
University of Illinois at Chicago, US

Keywords: nanomicelle, PEGylated phospholipid, Cancer, Rheumatoid arthritis


Vasoactive intestinal peptide (VIP) is a 28 amino acid endogenous neuropeptide with multiple biological functions. VIP receptors (R) are widely distributed in the extravascular spaces of the body, but they are not expressed in the endothelial lining of blood vessels. When VIP associated with a nanocarrier, is injected to blood, VIP receptors of normal tissues cannot be targeted. Therefore, VIP side effects can be totally eliminated. The only VIP receptors that VIP-R targeted nanomedicine can interact with, are the ones at the diseased tissues such as cancer or inflamed tissues with leaky vasculature, where the nanomedicine can extravasate out. Furthermore, VIP receptors are overexpressed in these diseased tissues providing a more effective targeting. In this presentation, results from animal studies using VIP-R targeted nanomedicines prepared with phospholipid nanomicelles carrying different drug molecules (anti- cancer and anti-inflammatory) will be demonstrated.